The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM
Not Applicable
Recruiting
- Conditions
- AFLD/NASH
- Registration Number
- JPRN-UMIN000036560
- Lead Sponsor
- ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. pregnant woman or lactating mother 2. poorly controlled heart failure 3. poorly controlled hypertension or diabetes 4. severe renal disorder 5. decompensated liver cirrhosis 6. other liver diseases, including autoimmune hepatitis, primary biliary cholangitis and alcoholic hepatitis, liver failure 7. positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 8. hypercarcemia 9. hyperparathyroidism 10. Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The liver function after Canagliflozin administration for 24weeks
- Secondary Outcome Measures
Name Time Method 1. The lipid and glycometabolism after Canagliflozin administration for 24weeks 2. The safety of Canagliflozin